Clinicopathological significance of CHFR promoter methylation in gastric cancer: a meta-analysis.
Clinicopathological significance of CHFR promoter methylation in gastric cancer: a meta-analysis.
复制标题
DOI：
10.18632/oncotarget.23394
复制
发表时间：
2018-02-09
期刊：
影响因子：
--
通讯作者：
Du, Yaowu
中科院分区：
文献类型：
--
作者：
Ding, Yong;Lian, Hai-Feng;Du, Yaowu
有丝分裂检查点基因（CHFR）（具有叉头相关和环指结构域的检查点）是G2期/有丝分裂检查点和肿瘤抑制基因。最近的研究报道了CHFR启动子甲基化与胃癌临床病理意义的关系。然而，由于样本量小，结果尚不清楚。我们汇集了15项研究，包括827例胃癌患者，并进行了荟萃分析，以探讨胃癌中CHFR启动子甲基化的临床病理意义。我们的数据显示，胃癌中CHFR启动子甲基化的频率高于正常胃组织，奇数比（OR）为10.12,95% CI为5.17-19.79,p < 0.00001。此外，CHFR启动子甲基化率在高级别胃癌中显著高于低级别胃癌，OR为1.64,95% CI为1.00-2.68,p = 0.05。CHFR甲基化与淋巴结转移阳性相关，OR为1.56,95% CI 1.05 ~ 2.32, p = 0.03。我们认为CHFR可以作为胃癌诊断的生物标志物，以及开发胃癌基因治疗的药物靶点。CHFR启动子甲基化与肿瘤分化不良和淋巴结转移有关。
The mitotic checkpoint gene (CHFR) (Checkpoint with Forkhead-associated and Ring finger domains is a G2 phase/mitosis checkpoint and tumor-suppressor gene. Recent studies have reported the relationship of CHFR promoter methylation with clinicopathological significance of gastric cancer. However, the results remain unclear due to small size of sample. We pooled 15 studies including 827 gastric cancer patients and conducted a meta-analysis to investigate the clinicopathological significance of CHFR promoter methylation in gastric cancer. Our data revealed that the frequency of CHFR promoter methylation was higher in gastric cancer than in normal gastric tissue, Odd Ratio (OR) was 10.12 with 95% CI 5.17-19.79, p < 0.00001. Additionally, the rate of CHFR promoter methylation was significantly increased in high grade of gastric cancer compared to low grade, OR was 1.64 with 95% CI 1.00-2.68, p = 0.05. CHFR methylation was significantly associated with the positive lymph node metastasis, OR was 1.56 with 95% CI 1.05-2.32, p = 0.03. We concluded that CHFR could serve as a biomarker for diagnosis of gastric cancer, and a drug target for development of gene therapy in gastric cancer. CHFR promoter methylation is associated with tumor poor differentiation and lymph node metastasis.